E-Z-Em gains distribution rights for Gadolite
Pharmacyclics has signed over the North American marketing anddistribution rights for the oral MRI contrast agent Gadolite toE-Z-Em of Westbury, NY. E-Z-Em is by far the market leader in the sale of barium contrastfor gastrointestinal x-ray procedures.
Pharmacyclics has signed over the North American marketing anddistribution rights for the oral MRI contrast agent Gadolite toE-Z-Em of Westbury, NY.
E-Z-Em is by far the market leader in the sale of barium contrastfor gastrointestinal x-ray procedures. As part of the agreement,the companies will collaborate on additional oral agents basedon Gadolite. Financial terms were not disclosed.
The agent has shown promise for abdominal and pelvic imaging,according to the company. Phase III trials were completed in thefirst quarter of 1995. Pharmacyclics expects to file a new drugapplication with the Food and Drug Administration by year-end.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
